E RGEBNISSE DER L ITERATURRECHERCHE : A NZAHL DER S TUDIEN

Im Folgenden Teil sind die Ergebnisse und die Anzahlen der Studien der Literaturrecherche anhand der bei der Recherche durchgeführten Reihenfolge aufgeführt.

3.1.1 Ergebnisse der Datenbankrecherche

Der Suchstring ergab nach der Eingabe bei der Datenbank „PubMed“ eine Anzahl von 2229 Abstracts, die in den weiteren Prozess der Datenextraktion eingegangen sind.

3.1.2 Ergebnisse der Abstract-Analyse

Die 2229 Abstracts wurden im Hinblick auf die Fragestellung gelesen und geprüft. Hierbei ergaben sich 39 Abstracts, die im Sinne der Fragestellung dieser Arbeit passend waren und bei denen zur weiteren Beurteilung der Studien daraufhin die Volltexte herangezogen wurden.

Diese wurden anschließend auf die oben beschriebenen vier definierten Untersuchungsaspek-te hin unUntersuchungsaspek-tersucht.

Die folgende Tabelle zeigt eine Übersicht derjenigen Studien, bei denen eine Untersuchung der Volltexte stattgefunden hat (Tabelle 3).

Tabelle 3: Studien mit anschließender Volltextanalyse (Es wird nur der Erstautor/die Erstau-torin angegeben)

1. Anderson, 2000 Gemcitabine plus best supportive care (BSC) vs. BSC in inoper-able non-small cell lung cancer - a randomized trial with quality of life as the primary outcome¹

2. Anderson, 2013 Degarelix versus goserelin (+ antiandrogen flare protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Pros-tate Cancer: Results from a Phase IIIb Study

3. Baka, 2005 Randomized phase II study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky perfor-mance status ≤ 70) and Advanced Non-Small-Cell Lung Cancer 4. Belani, 2006 Effect of chemotherapy for advanced non-small cell lung cancer

on patients' quality of life. A randomized controlled trial 5. Bernhard, 2008 Clinical Benefit and Quality of Life in Patients With

Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial

1Auf die Angabe der Seite wird verzichtet, da es sich um die Überschriften der zugrundeliegenden Publikationen handelt.

6. Bezjak, 2004 Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study

7. Biesma, 2011 Quality of life, geriatric assessment and survival in elderly pa-tients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study

8. Bonnetain, 2005 Longitudinal quality of life study in patients with metastatic gas-tric cancer

Analysis modalities and clinical applicability of QoL in random-ized phase II trial in a digestive oncology

9. Bottomley, 2004 Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line

Chemotherapy in Patients With Metastatic Breast Cancer: Euro-pean Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study

10. Bukowski, 2007 Effects of Sorafenib on Symptoms and Quality of Life

Results From a Large Randomized Placebo-Controlled Study in Renal Cancer

11. Burris, 1997 Assessing Clinical Benefit in the Treatment of Pancreas Cancer:

Gemcitabine Compared to 5-Fluorouracil

12. Cassier, 2008 A phase-III trial of doxorubicin and docetaxel versus doxorubi-cin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

13. Castellano, 2009 Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European pop-ulation

14. Colombo, 2012 A phase II study of aflibercept in patients with advanced epithe-lial ovarian cancer and symptomatic malignant ascites

15. Corey-Lisle,2012 Q-TWiST Analysis of Ixabepilone in Combination With Capeci-tabine on Quality of Life in Patients With Metastatic Breast Cancer

16. Cufer, 2006 Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in pa-tients with advanced (stage IIIb or IV) non-small-cell lung can-cer

17. Duvic, 2002 Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®)

18. Eckhardt, 2009 Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Ad-vanced Pancreatic Cancer

19. Gebbia, 2010 First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridio-nale

20. Girling, 1996 Comparison of oral etoposide and standard intravenous drug chemotherapy for small-cell lung cancer: a stopped multi-centre randomised trial

21. Glimelius, 1997 Randomized comparison between chemotherapy plus best sup-portive care with best supsup-portive care in advanced gastric cancer 22. Glimelius, 1994 Quality of life during Chemotherapy in Patients with

Sympto-matic Advanced Colorectal Cancer

23. Glimelius, 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

24. Gotlieb, 2012 Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study 25.

Gourgou-Bourgade, 2013

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer:

Results From the PRODIGE 4/ACCORD 11 Randomized Trial

26. Gronberg, 2009 Phase III Study by the Norwegian Lung Cancer Study Group:

Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–

Small-Cell Lung Cancer

27. Hirsh, 2013 Symptom and Quality of Life Benefit of Afatinib in Advanced Non-Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III trial (LUX-Lung 1)

28. Levy, 2001 Evaluating treatment strategies in chronic lymphocytic leukemia:

use of quality-adjusted survival analysis

29. Logothesis, 2012 Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 ran-domised trial

30. McQuellon, 2006 Quality of life (QOL) outcomes from a randomized trial of cis-platin versus ciscis-platin plus paclitaxel in advanced cervical cancer:

a Gynecologic Oncology Group study

31. Osoba, 2002 Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer 32. Osoba, 1999 Health-Related Quality of Life in Men With Metastatic Prostate

Cancer Treated With Prednisone Alone
or Mitoxantrone and Prednisone

33. Svensson, 2013 Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

34. Tannock, 1996 Chemotherapy With Mitoxantrone Plus Prednisone or Predni-sone Alone for Symptomatic Hormone-Resistant Prostate Can-cer: A Canadian Randomized Trial With Palliative End Points 35. Vansteenkiste,

2001

Clinical-benefit response in advanced non-small-cell lung cancer:

A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

36. Vinante, 1993 The Combination of Mitomycin, Vinblastine and Cisplatin is Active in the Palliation of Stage IIIB-IV Non-Small-Cell Lung Cancer

37. Yang, 2013 Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

38. Yang, 2010 Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α

39. Zbrozek, 2010 Q-TWiST Analysis of Patients Receiving Temsirolimus or Inter-feron Alpha for Treatment of Advanced Renal
Cell Carcinoma